Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects

Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects

Abstract SKLB1028 is a novel multi‐target protein kinase inhibitor under investigation for the treatment of FLT3‐ITD mutated acute myeloid leukemia. Based on the preclinical characterization of SKLB1028 metabolism, three drug–drug interaction clinical studies were performed to investigate the effect...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingcheng Chen, Jingxuan Wu, Nini Guo, Yuqin Song, Lijun Li, Bingyan Wang, Jiangshuo Li, Mengyu Hou, Hang Yin, Meijuan Zhang, Yanhong Kong, Xiaofang Wu, Ran Li, Le Wu, Qiannan Gao, Ruihua Dong
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.70063
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70063

Similar Items